Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study
Actas Dermo-Sifiliográficas · 2023-07 · 114 (7) · 565-571
DOI: 10.1016/j.ad.2023.04.022 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Actas Dermo-Sifiliográficas, 2023-07. Verfasst von O M Moreno-Arrones und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid,…. Hauptthemen laut MEDLINE: Skin Neoplasms, Basal Cell Carcinoma, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sun Pharmaceutical Industries Ltd.
Abstract (Originalsprache)
BACKGROUND: Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment. OBJECTIVE: To describe the use of sonidegib in a large number of patients and provide more data on its real-life efficacy and safety profile. METHODS: We conducted a retrospective and multicentric study that included patients treated with sonidegib. Epidemiological, effectiveness and safety data were collected. RESULTS: A total of 82 patients with a mean age of 73.9 years were included. Ten patients had Gorlin syndrome. Median treatment duration was 6 months. Median follow-up duration was 34.2 months. Globally, 81.7% of the patients showed clinical improvement (52.4% partial response and 29.3% complete response), 12.2% clinical stability and 6.1% disease progression. There was no statistically significant difference in clinical improvement between the 24h and 48h sonidegib posology. After 6 months of treatment, 48.8% of the patients discontinued sonidegib. Prior vismodegib treatment and recurrent primary BCC were associated with a poorer response to sonidegib. At 6 months of treatment, 68.3% of the patients experienced at least one adverse effect. CONCLUSION: Sonidegib shows good effectiveness and acceptable safety profile in usual clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Electronic address: o.m.m.arrones@gmail.com.
- Dermatology Department, Ramon y Cajal University Hospital, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.
- Department of Dermatology, Consorci Hospital General Universitari de Valencia, Valencia, Spain.
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Department of Dermatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Förderung
- Sun Pharmaceutical Industries Ltd
Zitieren
APA
Moreno-Arrones, O. M., Béa-Ardebol, S., Mayo-Martinez, F., Pérez-Pastor, G., Torres-Navarro, I., Bonfill-Ortí, M., Deza, G., Ruiz-Salas, V., Masferrer, E., Feal, C., Turrión-Merino, L., Toll, A., Yébenes, M., Galiano-Mejías, S., Jaka, A., Ferrandiz-Pulido, C., Florez, A., Hernández-Hernández, N., Fernández-de-Misa, R., …, & Sanmartin, O. (2023). Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study. Actas Dermo-Sifiliográficas, 114(7), 565-571. https://doi.org/10.1016/j.ad.2023.04.022
Vancouver
Moreno-Arrones OM, Béa-Ardebol S, Mayo-Martinez F, Pérez-Pastor G, Torres-Navarro I, Bonfill-Ortí M, et al. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study. Actas Dermo-Sifiliográficas. 2023;114(7):565-571. doi:10.1016/j.ad.2023.04.022
BibTeX
@article{MorenoArrones2023,
author = {Moreno-Arrones, O M and Béa-Ardebol, S and Mayo-Martinez, F and Pérez-Pastor, G and Torres-Navarro, I and Bonfill-Ortí, M and Deza, G and Ruiz-Salas, V and Masferrer, E and Feal, C and Turrión-Merino, L and Toll, A and Yébenes, M and Galiano-Mejías, S and Jaka, A and Ferrandiz-Pulido, C and Florez, A and Hernández-Hernández, N and Fernández-de-Misa, R and Rios-Buceta, L and Sanmartin, O},
title = {Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study},
journal = {Actas Dermo-Sifiliográficas},
year = {2023},
volume = {114},
number = {7},
pages = {565--571},
doi = {10.1016/j.ad.2023.04.022}
}
EUVIMED